GENBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Generate Biomedicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$12.56+0.47 (+3.89%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
6 of Generate Biomedicines's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Aug 25, 2026 | Aug 26, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 6, 2026 | Aug 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 6, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 7, 2026 | SEC EDGAR |
| Current report | 8-K | May 7, 2026 | May 7, 2026 | SEC EDGAR |
| Current report | 8-K | Feb 26, 2026 | Mar 2, 2026 | SEC EDGAR |